Objective:

To develop a new agent, LXG6403, targeting lysyl oxidase (LOX) to treat triple-negative breast cancer.

Approach:

• Research Methodology: Combined MALDI-MS imaging with extracellular matrix (ECM)-targeted proteomics to visualize protein architecture in tumors.

Key Findings:

• LXG6403 targets lysyl oxidase (LOX), a driver of aggressive tumorigenesis in triple-negative breast cancer.
• The inhibitor significantly impacts the extracellular matrix, collagen, and other structural proteins.

Interpretation:

Limitations:

• The study is in the preclinical phase, and clinical trials are pending approval.

Conclusion:

Sources:

• Medical University of South Carolina